Drugs / activated prothrombin complex concentrate (aPCC) FEIBA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05020483 | Oct 2021 → Dec 2023 | heart disorder | Mayo Clinic | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | activated prothrombin complex concentrate (aPCC) FEIBA | “activated prothrombin complex concentrate (aPCC) FEIBA” NCT05020483 ↗ |
| Known as | FEIBA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05020483 ↗ |
| Modality | Protein / enzyme biologic | “activated prothrombin complex concentrate (aPCC) FEIBA” NCT05020483 ↗ |
| Route | Intravenous | “Administered via the central line catheter” NCT05020483 ↗ |